Canton Strategic Holdings Inc
Canton Strategic Holdings Inc
- Market cap
- $98.78M
Your view on CNTN
Overview
What the company does, where it operates, and who runs it.
About Canton Strategic Holdings Inc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Wendland
- Headquarters
- 34 Shrewsbury Avenue, Red Bank, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Wendland
- Headquarters
- 34 Shrewsbury Avenue, Red Bank, NJ, US
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas.
The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development.
Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial.
Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Canton Strategic Holdings Inc. Starting points for Canton Strategic Holdings Inc: EPS -$0.60, beta 1.51 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Canton Strategic Holdings Inc. Trailing twelve-month EPS for Canton Strategic Holdings Inc stands at -$0.60. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Canton Strategic Holdings Inc. Canton Strategic Holdings Inc has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| QTTBQ32 Bio Inc. | Healthcare | NASDAQ | $249.6M | ||
| QUREuniQure N.V. | Healthcare | NASDAQ | $1.4B | ||
| RAC.AXRace Oncology Limited | Healthcare | ASX | — | ||
| RAD.AXRadiopharm Theranostics Limited | Healthcare | ASX | — | ||
| RADXRadiopharm Theranostics Limited | Healthcare | NASDAQ | $812,081 | ||
| RANIRani Therapeutics Holdings, Inc. | Healthcare | NASDAQ | $33.4M | ||
| RAPPRapport Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $1.1B | ||
| RAREUltragenyx Pharmaceutical Inc. | Healthcare | NASDAQ | $1.7B | ||
| RASPActavia Life Sciences, Inc. | Healthcare | OTC | $385,906 | ||
| RBSHRebus Holdings, Inc. | Healthcare | OTC | $3,213 | ||
| RCARRenovaCare, Inc. | Healthcare | OTC | $8,735 | ||
| RCE.AXRecce Pharmaceuticals Ltd | Healthcare | ASX | — | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Canton Strategic Holdings Inc, and how their positions are changing. At a $98.8M market value, institutional positions materially move Canton Strategic Holdings Inc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Canton Strategic Holdings Inc executives and directors. Shares of Canton Strategic Holdings Inc have traded between $1.08 and $9.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Canton Strategic Holdings Inc. Coverage tracks Canton Strategic Holdings Inc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Canton Strategic Holdings Inc.